Skip to content

Role of carbon nanoparticle suspension in sentinel lymph node biopsy for early-stage cervical cancer

Role of carbon nanoparticle suspension in sentinel lymph node biopsy for early-stage cervical cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000033473
Enrollment
Unknown
Registered
2020-06-01
Start date
2017-05-01
Completion date
Unknown
Last updated
2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

early-stage cervical cancer

Interventions

Gold Standard:Pathological diagnosis of pelvic lymph nodes, sentinel lymph nodes
Index test:carbon&#32
suspension&#32
(CNS)

Sponsors

The First Affiliated Hospital of Zhengzhou University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
23 Years to 68 Years

Inclusion criteria

Inclusion criteria: FIGO 2009 stages Ia2–IIa2; squamous cell carcinoma or typical adenocarcinoma (HPV-related); no evidence of bulky or suspicious PLNs, or distant metastases according to conventional imaging studies; surgery as the primary treatment; choose the operation method that does not preserve fertility function; and the provision of signed informed consent.

Exclusion criteria

Exclusion criteria: age younger than 18 years or older than 70 years; pregnancy; allergic history to activated carbon or high allergic constitution; incidence of other tumours within 5 years; contra-indication for surgical treatment; and intra-operative evidence of more advanced disease (>IIa2).

Design outcomes

Primary

MeasureTime frame
The overall SLNB detection rate;Diagnostic value of SLNB:sensitivity, specificity, False negative rate, positive predictive value, negative predictive value;

Countries

China

Contacts

Public ContactRuixia Guo

The First Affiliated Hospital of Zhengzhou University

fccguorx@zzu.edu.cn+86 13525569376

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026